We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioFocus and CHDI Foundation Enter new Five-Year Collaboration for Huntington’s Disease Therapeutics

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus and CHDI Foundation Enter new Five-Year Collaboration for Huntington’s Disease Therapeutics"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
BioFocus and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington’s disease, announced a new five-year collaboration focused on discovering novel drugs for Huntington’s disease. BioFocus will perform the research and is eligible to receive US$41 million (€31 million) in research fees during the five-year collaboration.

BioFocus will apply its full range of integrated drug discovery services for this program. Integrated biology and chemistry capabilities will be supported by BioFocus’ expertise in complex primary neuronal assay development, high-content screening, fragment-based screening, computational chemistry, ADME/PK and protein crystallography. The new agreement continues and expands the collaboration started in August 2005.

“Having collaborated with CHDI since 2005 in therapeutic target discovery, we are eager to continue working together to develop novel therapies for Huntington's disease and meet this urgent medical need,” said Onno van de Stolpe, CEO of Galapagos. “We are confident that the next five years of this long-standing relationship with CHDI will be as productive as the first five.”

“BioFocus has delivered expert technologies and experienced staff to therapeutic target and drug discovery research in the fight against Huntington’s disease,” said Ignacio Munoz-Sanjuan, Vice-President, Biology at CHDI. “This has encouraged us to extend and expand the collaboration, with the ultimate goal of finding disease-modifying treatments for Huntington’s.”